A Double-Layered Covered Biliary Metal Stent for the Management of Unresectable Malignant Biliary Obstruction: A Multicenter Feasibility Study.
- Author:
Jin Seok PARK
1
;
Seok JEONG
;
Don Haeng LEE
;
Jong Ho MOON
;
Kyu Taek LEE
;
Seok Ho DONG
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Stents; Extrahepatic cholestasis; Feasibility studies; Common bile duct neoplasms; Adverse effects
- MeSH: Cholangitis; Cholecystitis; Cholestasis; Cholestasis, Extrahepatic; Common Bile Duct Neoplasms; Feasibility Studies*; Follow-Up Studies; Humans; Liver Abscess; Medical Records; Pancreatitis; Retrospective Studies; Stents*; Tertiary Care Centers
- From:Gut and Liver 2016;10(6):969-974
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: The covered self-expandable metal stent (CMS) was developed to prevent tumor ingrowth-induced stent occlusion during the treatment of malignant biliary obstruction. However, complications such as cholecystitis, pancreatitis, and stent migration can occur after the endoscopic insertion of CMSs. The aim of the present study was to assess the efficacy and safety of a double-layered CMS (DCMS) for the management of malignant bile duct obstruction. METHODS: DCMSs were endoscopically introduced into 59 patients with unresectable malignant extrahepatic biliary obstruction at four tertiary referral centers, and the patient medical records were retrospectively reviewed. RESULTS: Both the technical and functional success rates were 100%. Procedure-related complications including pancreatitis, cholangitis, stent migration, and liver abscess occurred in five patients (8.5%). The median follow-up period was 265 days (range, 31 to 752 days). Cumulative stent patency rates were 68.2% and 40.8% at 6 and 12 months, respectively. At the final follow-up, the rate of stent occlusion was 33.9% (20/59), and the median stent patency period was 276 days (range, 2 to 706 days). CONCLUSIONS: The clinical outcomes of DCMSs were comparable to the outcomes previously reported for CMSs with respect to stent patency period and complication rates.
